NAG-1 H Variant (N-Term) antibody

Catalog No. ABIN964693

Product Details

Target: NAG-1 H Variant

Binding Specificity: N-Term

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: ELISA, Western Blotting (WB)

Specificity: This product was purified from concentrated tissue culture supernatant Protein A chromatography.  This antibody specifically reacts with an H variant sequence of human NAG-1 protein from human tissues.  A BLAST analysis was used to suggest partial reactivity with NAG-1 from chimpanzee and macaque based on a 92% homology.  Cross-reactivity with NAG-1 from other sources has not been determined.

Characteristics: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.

Purification: purified

Sterility: Sterile filtered

Immunogen: This Protein A purified antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the amino terminal end of human NAG-1 protein.  A residue of cysteine was added to facilitate coupling to KLH.
Immunogen Type: Peptide

Clone: 7C12-B3-F2

Isotype: IgG2b kappa

Application Details

Application Notes: This Protein A purified antibody is suitable for ELISA and western blotting of human NAG-1 protein.  This reagent is particularly useful to differentiate polymorphic forms of NAG-1 protein present in human serum samples.  This antibody is useful in dual antibody immunometric assays (EIA).  Expect bands in Western blots of approximately 14 and 28 kDa in size corresponding to NAG-1 monomer and dimer, respectively, using the appropriate cell lysate or extract. Specific conditions for reactivity should be optimized by the end user.

Comment:

Gene Name: GDF15

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1.33 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Store vial at 4 °C prior to restoration. For extended storage aliquot contents and freeze at -20 °C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening.

Expiry Date: 12 months

Target Details

Target: NAG-1 H Variant

Background: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.
Synonyms: NAG-1, GDF15, MIC-1, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, prostate-derived factor

Gene ID: 9518

UniProt: Q99988